Objectives: The trial aimed to explore putative imaging markers to help inform future clinical trial design of PBT2 in Alzheimer’s disease (AD).
Methods: We conducted a 52-week double-blind, randomized , placebo controlled trial involving 42 patients with mild AD (71.1+/-9.2 years, MMSE 24.2+/-2.5) with a baseline C-PiB-SUVR≥1.7. Participants received either PBT2 (250 mg/day) or placebo for 52 weeks. Primary outcome measure was Aβ burden as measured by C-PiB-PET at baseline and 12 months. Participants also underwent periodic neuropsychological evaluation, FDG-PET and MRI scans.
Results: PBT2 was well tolerated. At baseline, there were no significant between-group differences in age, gender, ApoE, hippocampal volume, PiB or FDG SUVR. Baseline C-PiB SUVR ranged between 1.73 and 3.31 (median 2.5). Despite PBT2-treated patients showing a significant decrease in Aβ burden at 12 months (-2.5%, p=.048) post-hoc, this was accompanied by a similar decrease in the placebo group (-3.1%, p=0.06), yielding no significant between-group differences. Similarly, no significant between-group differences were found on cognition, FDG or MRI volumetrics, though a trend towards a slower rate of hippocampal atrophy on the PBT2-treated patients (p=0.09) was observed. When analyzed separately, PBT2-treated participants with baseline >2.5 SUVR (n=11) showed significant reductions in PiB-SUVR (p=0.002) while those withConclusions: There were no between-group differences in Aβ burden in PBT2 treated and untreaded mild AD patients, despite a significant reduction in Aβ in the PBT2-treated patients, especially in those with a baseline PiB-SUVR ≥2.5.
- Forums
- ASX - By Stock
- ATH
- AD PD 2015 Victor Villemagne's Abstract
AD PD 2015 Victor Villemagne's Abstract
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $3.631K | 1.210M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
60 | 81072032 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 2447647 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
60 | 81072032 | 0.002 |
23 | 125810099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 2447647 | 3 |
0.004 | 138755246 | 32 |
0.005 | 21959256 | 23 |
0.006 | 22031950 | 18 |
0.007 | 50806651 | 22 |
Last trade - 15.59pm 18/09/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |